Clinical trial

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

NCT06341426

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Single Psychedelic Dose Psilocybin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Two Psychedelic Doses Psilocybin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-02-05

PhasePHASE2

Conditions

Major Depressive Disorderverified · MONDO: major depressive disorder

Depressionverified · MONDO: depressive disorder

Treatment-Resistant Depressionunresolved

Mood Disordersunresolved

Interventions

Single Psychedelic Dose PsilocybinDRUG

Two Psychedelic Doses PsilocybinDRUG

Sponsors & collaborators

University Health Network, Torontolead sponsor

Centre for Addiction and Mental Healthcollaborator

Mapped research locations

TorontoOntario, Canada2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06341426 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.